newsfilter
← Latest News
GlobeNewswire·

INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC

INMB
  • INmune Bio announced new Phase 2 imaging data for XPro in early Alzheimer's disease patients, showing early treatment-related changes in white matter myelin & cortical microstructure at Week 24.
  • Advanced MRI analyses revealed statistically significant treatment differences in white matter myelin integrity (p < 0.01) within the modified intent-to-treat population, with larger effects in patients selected via biomarker enrichment.
  • Concordant changes were observed across independent white matter & gray matter imaging endpoints using chi-separation for myelin & cortical disarray measurement for microstructure, supporting the interpretation of treatment-related biological effects.
  • Dr. CJ Barnum stated that detecting myelin integrity changes within 24 weeks & corroborating gray matter effects suggests XPro engages relevant biology earlier than traditional volumetric approaches.
  • CEO David Moss highlighted the robustness of XPro's effect on myelination & the potential of selective soluble TNF inhibition to reduce pathological neuroinflammation.
  • INmune Bio will present these findings at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12–15, 2026, under poster Abstract Control No. 13497.
  • The presentation includes longitudinal analyses, subgroup data, & mechanistic context for both white matter myelin & cortical microstructure endpoints from the MINDFuL study.
  • XPro1595 holds FDA Fast Track designation & follows a successful End-of-Phase 2 meeting, positioning it for a Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer's disease.
  • INmune Bio is also advancing its CORDStrom platform toward regulatory filings with the UK MHRA, EU EMA, & US FDA in 2026.